Trials / Completed
CompletedNCT01309477
The Efficacy and Tolerance of Tacrolimus Sustained-release Capsules on Refractory Nephrotic Syndrome (RNS)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 14 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
It is a pilot study to explore the efficacy and safety of Tacrolimus Sustained-release Capsules (ADVAGRAF) on 6-month induction therapy of Refractory Nephrotic Syndrome (RNS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tacrolimus Sustained-release Capsules (ADVAGRAF) | Started: 0.05-0.1mg/kg/d, one time per day, then adjusting the dose to maintain the blood level 5-10ng/ml in the induction treatment . |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2011-03-07
- Last updated
- 2011-11-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01309477. Inclusion in this directory is not an endorsement.